SUPN
SUPERNUS PHARMACEUTICALS, INC.
$44.48
-0.60%
$2.7B
No data for this timeframe.
Vol
Market Cap$2.7B
Cap SizeMid Cap
Inst. Holders9 funds
Inst. Value$522.4M
Inst. Activity3 buys / 2 sells
Insider Activity0B / 10S
Insider Net $-$6.5M
SEC Reports7
Recent Activity
May 20, 2026
SEC
Supernus notified the CVR rights agent that Milestone 1 was achieved on March 18, 2026, triggering a $0.50-per-CVR cash
8-K — Impact 3/10
Apr 22, 2026
SEC
Supernus Pharmaceuticals announced it will report its Q1 2026 financial results on May 5, 2026, after market close. This
8-K — Impact 2/10
Apr 22, 2026
SEC
Supernus Pharmaceuticals announced it will report Q1 2026 financial results on May 5, 2026, with a subsequent conference
PRESS-RELEASE — Impact 3/10
Mar 18, 2026
Insider
Bhatt Padmanabh P. sold 7,250 shares
Sr. VP of IP, CSO @ $39.40 ($285.6K)
Mar 18, 2026
Insider
Bhatt Padmanabh P. sold 6,838 shares
Sr. VP of IP, CSO @ $49.55 ($338.8K)
Mar 18, 2026
Insider
Bhatt Padmanabh P. sold 7,250 shares
Sr. VP of IP, CSO @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — ADD
1,079,471 shares ($53.6M)
Inst.
BANK OF AMERICA CORP — TRIM
520,747 shares ($25.9M)
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$62.83 (Dec 2025)
Current $45.66
Low $55.00
Median $64.00
High $66.00
6 analysts
$55.00
$66.00
Analyst Ratings
4Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 19, 2025 | Stifel | MAINTAIN | Hold → Hold |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.46 ▼ -16.5% | $0.44 — $0.47 | -50% YoY | 2 |
| Next Q | $0.67 ▼ -7.4% | $0.59 — $0.75 | 10% YoY | 3 |
| Current FY | $2.49 ▲ +6.3% | $2.11 — $2.95 | 4% YoY | 3 |
| Next FY | $4.34 ▲ +2.9% | $3.77 — $4.76 | 75% YoY | 3 |
Latest Reports
NEUTRAL
8-K
3/10
Supernus notified the CVR rights agent that Milestone 1 was achieved on March 18, 2026, triggering a $0.50-per-CVR cash
May 20, 2026
NEUTRAL
8-K
2/10
Supernus Pharmaceuticals announced it will report its Q1 2026 financial results on May 5, 2026, after market close. This
Apr 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $300.6M | — |
| RENAISSANCE TECHNOLOGIES LLC | $86.1M | — |
| MORGAN STANLEY | $53.6M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $35.0M | NEW |
| BANK OF AMERICA CORP | $25.9M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 18, 2026 | Bhatt Padmanabh | M | $285.6K |
| Mar 18, 2026 | Bhatt Padmanabh | SELL | $338.8K |
| Mar 18, 2026 | Bhatt Padmanabh | M | $0.00 |
| Mar 17, 2026 | Bhatt Padmanabh | M | $896.4K |
| Mar 17, 2026 | Bhatt Padmanabh | SELL | $1.4M |
9 institutional holders with $522.4M total value (10,511,326 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 6,048,496 | $300.6M | 57.5% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,732,522 | $86.1M | 16.5% | — |
| 3 | MORGAN STANLEY | 1,079,471 | $53.6M | 10.3% | ADD +42.9% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 703,625 | $35.0M | 6.7% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 520,747 | $25.9M | 5.0% | TRIM -38.2% |
| 6 | FMR LLC | 124,331 | $6.2M | 1.2% | — |
| 7 | TWO SIGMA INVESTMENTS, LP | 120,666 | $6.0M | 1.1% | TRIM -53.2% |
| 8 | NORGES BANK | 120,396 | $6.0M | 1.1% | NEW |
| 9 | WELLS FARGO & COMPANY/MN | 61,072 | $3.0M | 0.6% | ADD +46.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 755,317 | 1,079,471 | +42.9% | $53.6M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 842,890 | 520,747 | -38.2% | $25.9M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 257,976 | 120,666 | -53.2% | $6.0M | 2025-Q4 |
| NORGES BANK | NEW | — | 120,396 | — | $6.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 41,766 | 61,072 | +46.2% | $3.0M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 504,306 | 842,890 | +67.1% | $40.3M | 2025-Q3 |
| UBS Group AG | DOUBLED | 227,348 | 540,123 | +137.6% | $25.8M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 57,305 | 257,976 | +350.2% | $12.3M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 70,236 | 41,766 | -40.5% | $2.0M | 2025-Q3 |
| NORGES BANK | EXIT | 31,405 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 97,224 | 57,305 | -41.1% | $1.8M | 2025-Q2 |
| NORGES BANK | NEW | — | 31,405 | — | $989.9K | 2025-Q2 |
| UBS Group AG | ADD | 200,026 | 250,316 | +25.1% | $8.2M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 112,540 | 176,614 | +56.9% | $5.8M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 24,987 | 97,224 | +289.1% | $3.2M | 2025-Q1 |
| NORGES BANK | EXIT | 125,551 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | ADD | 108,858 | 200,026 | +83.7% | $7.2M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 712,395 | — | $22.2M | 2024-Q3 |
10 unique insiders with 10 transactions. Net insider value: -$6.5M ($0.00 bought, $6.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 18, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | M | 7,250 | $39.40 | $285.6K |
| Mar 18, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | SELL | 6,838 | $49.55 | $338.8K |
| Mar 18, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | M | 7,250 | $0.00 | $0.00 |
| Mar 17, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | M | 22,750 | $39.40 | $896.4K |
| Mar 17, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | SELL | 27,710 | $49.95 | $1.4M |
| Mar 17, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | M | 22,750 | $0.00 | $0.00 |
| Mar 16, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | M | 22,750 | $36.75 | $836.1K |
| Mar 16, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | SELL | 34,114 | $50.18 | $1.7M |
| Mar 16, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | M | 22,750 | $0.00 | $0.00 |
| Mar 13, 2026 | Khattar Jack A. | President, CEO | J | 12,500 | $0.00 | $0.00 |
| Mar 13, 2026 | Khattar Jack A. | President, CEO | SELL | 24,138 | $50.09 | $1.2M |
| Mar 12, 2026 | Hudson Frederick M. | Director | SELL | 5,369 | $50.61 | $271.7K |
| Mar 10, 2026 | Horich William Todd | SVP, Commercial Operations | SELL | 4,439 | $55.00 | $244.1K |
| Mar 9, 2026 | Mottola Frank | SVP, Chief Tech. Ops. Officer | SELL | 1,623 | $53.65 | $87.1K |
| Mar 9, 2026 | Horich William Todd | SVP, Commercial Operations | SELL | 4,438 | $54.00 | $239.7K |
| Mar 6, 2026 | GEMAYEL GEORGES | Director | M | 7,905 | $25.30 | $200.0K |
| Mar 6, 2026 | DEC TIMOTHY C | Senior Vice-President & CFO | M | 3,000 | $0.00 | $0.00 |
| Mar 6, 2026 | DEC TIMOTHY C | Senior Vice-President & CFO | F | 1,433 | $54.73 | $78.4K |
| Mar 6, 2026 | DEC TIMOTHY C | Senior Vice-President & CFO | M | 3,000 | $0.00 | $0.00 |
| Mar 6, 2026 | Mottola Frank | SVP, Chief Tech. Ops. Officer | M | 3,750 | $0.00 | $0.00 |
| Mar 6, 2026 | Khattar Jack A. | President, CEO | M | 38,640 | $0.00 | $0.00 |
| Mar 6, 2026 | Khattar Jack A. | President, CEO | F | 16,574 | $54.73 | $907.1K |
| Mar 6, 2026 | Mottola Frank | SVP, Chief Tech. Ops. Officer | F | 1,793 | $54.73 | $98.1K |
| Mar 6, 2026 | Khattar Jack A. | President, CEO | M | 38,640 | $0.00 | $0.00 |
| Mar 6, 2026 | GEMAYEL GEORGES | Director | M | 7,905 | $0.00 | $0.00 |
| Mar 6, 2026 | GEMAYEL GEORGES | Director | SELL | 8,787 | $53.00 | $465.7K |
| Mar 6, 2026 | Horich William Todd | SVP, Commercial Operations | M | 2,625 | $0.00 | $0.00 |
| Mar 6, 2026 | Horich William Todd | SVP, Commercial Operations | F | 1,216 | $54.73 | $66.6K |
| Mar 6, 2026 | Horich William Todd | SVP, Commercial Operations | M | 2,625 | $0.00 | $0.00 |
| Mar 6, 2026 | Mottola Frank | SVP, Chief Tech. Ops. Officer | M | 3,750 | $0.00 | $0.00 |
| Mar 5, 2026 | GEMAYEL GEORGES | Director | SELL | 10,000 | $53.71 | $537.1K |
| Feb 28, 2026 | Khattar Jack A. | President, CEO | A | 38,640 | $0.00 | $0.00 |
| Feb 28, 2026 | DEC TIMOTHY C | Senior Vice-President & CFO | A | 3,000 | $0.00 | $0.00 |
| Feb 28, 2026 | Mottola Frank | SVP, Chief Tech. Ops. Officer | A | 3,750 | $0.00 | $0.00 |
| Feb 25, 2026 | Rubin Jonathan | SVP, Chief Medical Officer | A | 1,250 | $0.00 | $0.00 |
| Feb 25, 2026 | Rubin Jonathan | SVP, Chief Medical Officer | D | 1,250 | $0.00 | $0.00 |
| Feb 25, 2026 | Mottola Frank | SVP, Chief Tech. Ops. Officer | A | 1,875 | $0.00 | $0.00 |
| Feb 25, 2026 | Mottola Frank | SVP, Chief Tech. Ops. Officer | D | 1,875 | $0.00 | $0.00 |
| Feb 25, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | A | 1,250 | $0.00 | $0.00 |
| Feb 25, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | D | 1,250 | $0.00 | $0.00 |
| Feb 25, 2026 | DEC TIMOTHY C | Senior Vice-President & CFO | A | 2,500 | $0.00 | $0.00 |
| Feb 25, 2026 | DEC TIMOTHY C | Senior Vice-President & CFO | D | 2,500 | $0.00 | $0.00 |
| Feb 24, 2026 | Rubin Jonathan | SVP, Chief Medical Officer | D | 1,125 | $0.00 | $0.00 |
| Feb 24, 2026 | Mottola Frank | SVP, Chief Tech. Ops. Officer | A | 1,125 | $0.00 | $0.00 |
| Feb 24, 2026 | Mottola Frank | SVP, Chief Tech. Ops. Officer | D | 1,125 | $0.00 | $0.00 |
| Feb 24, 2026 | Barlow Carrolee | Director | D | 4,475 | $0.00 | $0.00 |
| Feb 24, 2026 | NEWHALL CHARLES W III | Director | D | 4,475 | $0.00 | $0.00 |
| Feb 24, 2026 | GEMAYEL GEORGES | Director | A | 4,475 | $0.00 | $0.00 |
| Feb 24, 2026 | Barlow Carrolee | Director | A | 4,475 | $0.00 | $0.00 |
| Feb 24, 2026 | NEWHALL CHARLES W III | Director | A | 4,475 | $0.00 | $0.00 |
7 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 4.4/10.
NEUTRAL
8-K
3/10
Supernus notified the CVR rights agent that Milestone 1 was achieved on March 18, 2026, triggering a
May 20, 2026
NEUTRAL
8-K
2/10
Supernus Pharmaceuticals announced it will report its Q1 2026 financial results on May 5, 2026, afte
Apr 22, 2026
NEUTRAL
PRESS-RELEASE
3/10
Supernus Pharmaceuticals announced it will report Q1 2026 financial results on May 5, 2026, with a s
Apr 22, 2026
BULLISH
8-K
7/10
Supernus Pharmaceuticals completed the acquisition of NV-5138/SPN-820 assets from Navitor Pharmaceut
Apr 7, 2026
NEUTRAL
CLUSTER
4/10
Two insiders at Supernus Pharmaceuticals sold shares in the past week, including a director and an S
Mar 16, 2026
NEUTRAL
CLUSTER
4/10
Multiple insiders at Supernus Pharmaceuticals sold shares in the past week, including SVP William To
Mar 10, 2026
BULLISH
8-K
8/10
Supernus Pharmaceuticals reported record financial results for Q4 and full year 2025, with total rev
Feb 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Dec 2025): 83% buy across 12 analysts — 4 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$62.83 mean target (Dec 2025)
$55.00 Low
$66.00 High
| Metric | Value |
|---|---|
| Current Price | $45.66 |
| Target Low | $55.00 |
| Target Mean | $62.83 |
| Target Median | $64.00 |
| Target High | $66.00 |
| # Analysts | 6 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.46 | $0.44 | $0.47 | -49.8% | -16.5% | 1↑ 0↓ | $0.2B | 24.3% | 2 |
| Next Q 2026-09-30 |
$0.67 | $0.59 | $0.75 | 9.7% | -7.4% | — | $0.2B | 14.3% | 3 |
| Current FY 2026-12-31 |
$2.49 | $2.11 | $2.95 | 3.8% | +6.3% | — | $0.9B | 20.6% | 3 |
| Next FY 2027-12-31 |
$4.34 | $3.77 | $4.76 | 74.7% | +2.9% | — | $1.0B | 17.6% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.455 | |
| 7d ago | $0.470 | -0.015 |
| 30d ago | $0.545 | -0.090 |
| 60d ago | $0.540 | -0.085 |
| 90d ago | $0.540 | -0.085 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 19, 2025 | Stifel | MAINTAIN | Hold | Hold |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| May 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Apr 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Feb 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Jan 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
Clinical Trial
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: SPN-812 (Phase 3)
Trial: Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
Sponsor: Supernus Pharmaceuticals,
May 27, 2026
other
Supernus Pharmaceuticals to Participate in June Investor Conferences
<p align="justify">ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focus
May 6, 2026
other
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
<p align="justify">ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focus
May 5, 2026
earnings
Supernus Announces First Quarter 2026 Financial Results
<p align="justify">ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focus
May 5, 2026
earnings_calendar
SUPN Q1 2026 Earnings Scheduled — 2026-05-05
Apr 22, 2026
earnings
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
<p align="justify">ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company foc
Apr 17, 2026
Clinical Trial
Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
Phase Phase 2 — COMPLETED
Feb 27, 2026
short_interest
FTD: SUPN — 31,056 shares ($1.7M) failed to deliver
Settlement: 20260227, Price: $55.75, FTD Value: $1,731,372, SUPERNUS PHARMACEUTICALS INC C
Feb 26, 2026
short_interest
FTD: SUPN — 19,032 shares ($1.1M) failed to deliver
Settlement: 20260226, Price: $56.32, FTD Value: $1,071,882.24, SUPERNUS PHARMACEUTICALS INC C
Feb 24, 2026
earnings_calendar
SUPN Q4 2025 Earnings After Market Close — 2026-02-24